RadNet, Inc. RDNT R2K

Healthcare · Diagnostics & Research · United States

https://www.radnet.com

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Market & Price

Market Cap

$4.37B

Current Price

$55.53

High / Low (52W)

$84.48 / $52.39

Beta

1.43

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

58.87

PEG Ratio

0.96

Book Value

$14.08

Price to Book

3.94

P/S

2.04

EV/EBITDA

24.19

Dividend Yield

Profitability & Returns

ROCE

3.21%

ROE

1.77%

ROA

1.58%

Profit Margin

-0.66%

Op Margin

-2.85%

EPS (Latest Qtr)

$-0.43

EPS (TTM)

$-0.17

Balance Sheet & Liquidity

Debt/Equity

1.43

Quick Ratio

1.05

Current Ratio

1.17

Debt

$1.93B

Total Assets

$3.76B

Current Assets

$1.03B

Working Capital

$445.36M

Ownership

Promoter Holding

9.95%

Chg in Prom Hold

FII / Inst Holding

100.04%

Chg in FII Hold

-0.01%

Financial Snapshot

Enterprise Value

$6.12B

Total Revenue (TTM)

$2.14B

EBITDA

$252.91M

Free Cash Flow

$190.47M

Operating Cash Flow

$336.31M

Shares Outstanding

78.63M

Gross Margin

17.20%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

12.57%

Profit 5Y

-91.71%

Revenue (YoY)

22.10%

Earnings (YoY)

PROS

Compounding revenue at 12.6% over 5 years.
Generates positive free cash flow.

CONS

Earnings shrank at -91.7% CAGR over 5 years.
Trading 34.3% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	RDNT RadNet, Inc. R2K	55.53	-	$4.37B	-	3.21%	1.77%	12.57%	-91.71%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	289.10M	292.69M	-	281.56M	190.57M	291.78M	315.32M	333.92M	332.69M	341.77M	354.38M	350.04M	390.56M	403.71M	401.97M	431.71M	459.71M	-	-	471.40M	498.23M	522.87M	547.71M	575.63M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	453.48M	429.08M	450.38M	471.78M	550.51M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17.92M	69.14M	72.49M	75.93M	25.12M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	35.48M	35.99M	39.80M	40.85M	44.97M
Operating Income	13.38M	17.23M	-	2.98M	8.08M	12.45M	-	6.75M	14.16M	10.84M	-	-888.00K	15.87M	16.45M	-	7.27M	21.98M	16.85M	-	-8.78M	179.00K	23.38M	17.65M	27.68M	32.57M	-1.72M	19.56M	6.92M	6.67M	24.44M	43.25M	11.34M	34.85M	-	-	-17.56M	33.15M	32.69M	35.08M	-19.85M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19.59M	77.04M	77.43M	139.76M	29.80M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17.24M	17.19M	17.36M	18.13M	17.66M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-33.13M	23.85M	20.27M	20.92M	-32.83M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3.40M	820.00K	6.38M	11.05M	-8.10M
Net Income	3.40M	7.99M	881.00K	-1.72M	3.62M	1.65M	3.68M	-1.21M	5.31M	3.23M	-7.28M	-7.34M	5.41M	5.04M	29.14M	-3.73M	4.90M	3.19M	10.40M	-16.36M	-10.59M	6.16M	9.46M	2.87M	16.22M	3.01M	7.91M	668.00K	-21.00M	8.37M	17.54M	-2.78M	-2.98M	-	-	-37.93M	14.45M	5.42M	-597.00K	-33.47M
Diluted EPS	0.08	0.18	0.02	-0.04	0.08	0.04	0.08	-0.03	0.11	0.07	-0.15	-0.15	0.11	0.10	0.59	-0.08	0.10	0.06	0.21	-0.33	-0.21	0.12	0.18	0.05	0.30	0.05	0.13	0.01	-0.36	0.12	0.25	-0.04	-0.04	0.04	-	-0.51	0.19	0.07	-	-0.43

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	975.15M	1.15B	1.07B	-	1.43B	1.62B	1.83B	2.04B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	1.26B	1.40B	1.58B	1.80B
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	165.72M	221.39M	249.12M	235.49M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	115.88M	128.39M	137.84M	152.13M
Operating Income	42.10M	41.71M	50.66M	12.64M	43.60M	53.30M	39.12M	38.48M	50.05M	30.89M	69.88M	35.68M	-	49.84M	93.00M	111.28M	83.36M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	278.53M	292.79M	323.10M	313.82M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	50.84M	64.48M	79.85M	69.91M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	42.97M	38.81M	44.86M	31.91M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	9.36M	8.47M	6.03M	14.86M
Net Income	-2.27M	-12.85M	7.23M	12.39M	2.12M	1.38M	7.71M	7.23M	53.00K	32.24M	14.76M	-14.84M	-	10.65M	3.04M	2.79M	-18.65M
Diluted EPS	-0.06	-0.35	0.19	1.52	0.05	0.03	0.17	0.15	0.00	0.66	0.29	-0.29	-	0.17	0.05	0.04	-0.25

Compounded Sales Growth

5 Years:	12.57%
1 Year:	22.10%

Compounded Profit Growth

5 Years:	-91.71%
1 Year:	-

Stock Price Performance

1 Year:	-3.41%
6 Months:	-33.02%
3 Months:	-20.46%
1 Month:	-0.64%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	539.51M	619.19M	710.86M	40.65M	740.68M	836.43M	849.48M	868.98M	1.11B	1.65B	1.79B	-	2.43B	2.69B	3.29B	3.76B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	367.18M	579.28M	1.02B	1.03B
Cash & Equivalents	-	10.09M	627.00K	2.09M	362.00K	8.41M	307.00K	446.00K	20.64M	51.32M	10.39M	40.16M	102.02M	-	127.83M	342.57M	740.02M	767.22M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	166.36M	163.71M	185.82M	200.32M
Total Liabilities	-	-	621.99M	689.00M	717.55M	5.64M	732.98M	799.97M	797.42M	799.05M	909.08M	1.41B	1.53B	-	1.94B	1.88B	2.15B	2.40B
Current Liabilities	-	-	105.26M	122.38M	119.04M	2.98M	133.27M	156.96M	155.34M	191.61M	239.52M	327.43M	398.11M	-	466.72M	437.45M	479.71M	586.76M
Long Term Debt	-	-	-	543.19M	573.76M	-	-	-	-	-	-	-	612.91M	-	839.34M	812.07M	991.57M	1.06B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.51B	1.49B	1.73B	1.86B
Total Equity	-81.03M	-74.76M	-82.47M	-69.81M	-6.68M	-80.00K	7.70M	36.46M	52.05M	61.56M	127.18M	151.69M	165.74M	-	333.00M	630.70M	902.31M	1.09B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	57.72M	67.96M	74.04M	77.40M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	76.62M	66.88M	57.64M	75.27M	66.42M	-	67.04M	91.64M	142.22M	116.75M	104.32M	233.76M	-	146.42M	220.86M	233.02M	298.82M
Investing Cash Flow	-36.28M	-101.38M	-87.74M	-87.05M	-50.66M	-	-96.80M	-65.49M	-79.32M	-146.75M	-99.47M	-126.24M	-	-246.95M	-201.47M	-233.07M	-343.87M
Financing Cash Flow	-30.24M	25.04M	31.93M	9.62M	-7.62M	-	29.94M	-5.91M	-32.25M	-10.87M	24.95M	-45.56M	-	93.65M	195.63M	397.95M	72.21M
Capital Expenditure	-30.75M	-40.29M	-42.72M	-1.09M	-48.62M	-41.74M	-42.96M	-59.25M	-61.34M	-72.18M	-74.15M	-	-	-119.45M	-176.60M	-188.07M	-213.25M
Free Cash Flow	45.87M	26.59M	14.92M	74.18M	17.80M	-	24.07M	32.39M	80.89M	44.57M	30.17M	-	-	26.97M	44.26M	44.95M	85.57M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-6.88M	215.03M	397.90M	27.16M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	11.6%	13.7%	13.6%	11.5%
Operating Margin %	-	-	-	-	-	-	-	-	-	3.2%	6.1%	3.3%	-	3.5%	5.8%	6.1%	4.1%
Net Margin %	-	-	-	-	-	-	-	-	-	3.3%	1.3%	-1.4%	-	0.7%	0.2%	0.2%	-0.9%
ROE %	3.0%	15.6%	-10.4%	-185.4%	-2,650.0%	17.9%	21.1%	13.9%	0.1%	25.4%	9.7%	-9.0%	-	3.2%	0.5%	0.3%	-1.7%
ROCE %	-	9.6%	10.2%	2.1%	115.8%	8.8%	5.8%	5.5%	7.4%	3.6%	5.3%	2.6%	-	2.5%	4.1%	4.0%	2.6%

Shareholding Pattern

Insiders

9.95%

Institutions

100.04%

Public Float

111.10%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	12.76%	10.04M	$557.28M
2	RTW Investments LP	5.45%	4.29M	$237.95M
3	Price (T.Rowe) Associates Inc	5.28%	4.15M	$230.72M
4	Vanguard Portfolio Management LLC	4.96%	3.90M	$216.52M
5	Beck, Mack & Oliver LLC	4.03%	3.17M	$175.82M
6	Vanguard Capital Management LLC	3.96%	3.11M	$172.75M
7	State Street Corporation	3.37%	2.65M	$147.24M
8	Geode Capital Management, LLC	2.19%	1.72M	$95.71M
9	Invesco Ltd.	2.08%	1.63M	$90.71M
10	JB Capital Partners LP	1.81%	1.42M	$79.08M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RDNT

No recent headlines available.

RDNT · Healthcare

RadNet, Inc.

About

Key Facts

Sector	Healthcare
Industry	Diagnostics & Research
Headquarters	United States
Employees	11,000
Website	https://www.radnet.com

Press Esc or click outside to close.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

RadNet, Inc. RDNT R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More